PF-AtlasClinical Trials › NCT06012500

Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease

Xenon-129 · Phase 1

Registry ID
NCT06012500
Phase
Phase 1
Status
Active, not recruiting
Drug / intervention
Xenon-129
Sponsor
Children's Hospital Medical Center, Cincinnati
Start
2022-04-14
Enrollment
78
Locations
1

About this trial

The purpose of this multi-centered, NIH-sponsored study is to to develop an optimal protocol for using non-invasive 129Xe gas exchange MRI to detect changing disease activity in interstitial lung diseases (ILDs). We base this study on the demonstrated promise of 129Xe as a biomarker for both prognosis and therapy response, overwhelming interest from both industry and academic partners, and impending FDA approval for 129Xe ventilation MRI. This requires disseminating standardized and repeatable methods for 3D 129Xe functional MRI in order to facilitate innovative multi-center observational and interventional trials that can advance our understanding of fibrotic lung disease, while accelerating the development of novel therapies.

View NCT06012500 on ClinicalTrials.gov →

Explore related

Medical disclaimer. This page summarizes public trial data for NCT06012500 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.